Fractyl Health (NASDAQ:GUTS) Trading 9.3% Higher

Fractyl Health, Inc. (NASDAQ:GUTS) shares rose 9.3% during mid-day trading on Wednesday . The stock traded as high as $6.20 and last traded at $6.10. Approximately 158,562 shares traded hands during trading, a decline of 44% from the average daily volume of 281,585 shares. The stock had previously closed at $5.58.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GUTS. Evercore ISI began coverage on Fractyl Health in a research note on Wednesday, February 28th. They issued an “outperform” rating for the company. Morgan Stanley began coverage on shares of Fractyl Health in a research report on Tuesday, February 27th. They issued an “overweight” rating and a $18.00 target price for the company. Finally, Bank of America began coverage on shares of Fractyl Health in a research report on Tuesday, February 27th. They set a “buy” rating and a $26.00 price target on the stock.

Fractyl Health Price Performance

The company has a debt-to-equity ratio of 0.34, a current ratio of 9.38 and a quick ratio of 9.37. The company’s 50 day moving average is $6.74.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.45). The business had revenue of $0.03 million during the quarter. As a group, analysts expect that Fractyl Health, Inc. will post -2.03 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Fractyl Health stock. American International Group Inc. purchased a new position in Fractyl Health, Inc. (NASDAQ:GUTS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,339,261 shares of the company’s stock, valued at approximately $9,911,000. American International Group Inc. owned about 2.80% of Fractyl Health as of its most recent SEC filing.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.